KeloidsEarly Phase 1NCT07531056
Comparison Of Effectiveness Of Intralesional Injectioms Of 5 Flourouracil Alone Verses Its Cpmbination With Cryotherapy In The Treatment Of Keloids
A Early Phase 1 study testing Cryotherapy will be done followed by intralesional injection of 5-fluorouracil and Intralesional 5-fluorouracil in people with Keloids, run by Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan at 1 site in Pakistan.
Trial summary
The goal of this clinical trial is to learn how well intralesional 5 fluorouracil with cryotherapy works to treat keloids as compared to intralesional 5 fluorouracil alone on keloids. It will also learn about the safety of both these treatments. Read more about this study
- Who is it for?
- Ages 18 to 50 years
- Conditions the study is for
- Keloids
- What is being tested?
- Cryotherapy will be done followed by intralesional injection of 5-fluorouracil and Intralesional 5-fluorouracil
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 88 participants
- Where
- 1 sitePakistan
- Study dates
- 22 Dec 2025to 20 Sep 2026
- Phase
- Early Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Patients willing to participate in the study
- Patients of age group of 18 -50 years.
- Patients having symptomatic keloids i.e., having pain, pruritus, restriction of movement, scar tension or disfigurement.
Who cannot join
- :• Pregnant women or lactating women
- Patients with history of hepatic, renal, cardiac diseases or chronic diarrhea.
- Patients on immunosuppressant medications due to other diseases
- Patients having myelosuppression checked by CBC.
- Patient taking warfarin.
- Patients with history of hypersensitivity to 5FU.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Pakistan1 site, 1 recruiting
- Recruiting
CMH Bahawalpur
Chak Eighty-seven -Twelve Left
Areeba Sadia, +923336881616, areebasadiahadia@gmail.com
About this study
Official title: A Randomized Controlled Trial Comparing The Effectiveness And Safety Of iIntralesional 5 Flourouracil Monotherapy Verses 5 Flourouracil Combined With Cryotherapy; In The Treatment Of Keloid Scars
The goal of this clinical trial is to learn how well intralesional 5 fluorouracil with cryotherapy works to treat keloids as compared to intralesional 5 fluorouracil alone on keloids. It will also learn about the safety of both these treatments. The main questions it aims to answer are:
- What well does cryotherapy followed by intralesional 5 fluorouracil (5FU) work to treat keloids as compared to 5 fluorouracil (5FU) alone?
- What is participant's satisfaction when treated with cryotherapy followed by intralesional 5 fluorouracil (5FU) as compared to 5 fluorouracil (5FU) alone?
- What skin problems do participants have when treated with cryotherapy followed by intralesional 5 fluorouracil (5FU) and 5 fluorouracil (5FU) alone? Researchers will compare cryotherapy followed by intralesional 5 fluorouracil (5FU) with 5 fluorouracil (5FU) alone to see how well both work.
Read more
Participants will be divided into two groups:
For Group A: Cryotherapy will be done at lesion site followed by intralesional 5FU every 3 weekly.
For Group B: Intralesional 5FU will be given at lesion site every 3 weekly. Keloids will be assessed at the start of trial and then after 12 weeks of treatment.
Read the detailed description
The rationale of this study is to find cost-effective treatment regime of cryotherapy with intralesional 5 fluorouracil for keloids. Investigator aim to compare how effective is the combination of cryotherapy followed by intralesional 5 fluorouracil (5FU) as compared to 5 fluorouracil (5FU) alone in the treatment of keloids.
88 patients with keloids consulting the dermatologist in the hospital OPD will be included in the trial after application of the mentioned inclusion and exclusion criteria. After informed consent, a dermatologist will explain the required details of the procedure to the patients and give them their required treatment plan. Participanys will be randomized into two groups by lottery method. Demographic data like age, gender, location, duration, number of keloids, Fitzpatrick skin type, family history of keloids, keloid symptoms (pain, itching or disfigurement), previous treatments (topical steroids, topical silicone sheet or cream, cryotherapy, surgical excision, intralesional steroids or none) will be recorded along with the baseline photograph and rating of severity score based on DSS score. For Group A, Cryotherapy will be done by a spray mini-cryogun ( Brymill B800 Cry-Ac 3 dispenser) using liquid nitrogen targeted at the lesion from the distance of 1 cm and freeze thaw cycles of 30 seconds will be repeated till the lesion freezes to the level of its contact with skin. With larger lesions 2cm2 area will be targeted in a stepwise manner to ensure homogenous cryotherapy of the entire lesion. Local anaesthesia will be given before the cryotherapy with bupivacaine injection, as it relives pain up to 72 hours. 30 minutes after the cryotherapy session intralesional injection of 5 fluorouracil 50mg/ml 0.75ml mixed with 0.25ml triamcinolone acetonide 10mg/ml for every 2cm2 of keloid using a 30-gauge needle with a 3cc syringe. Not to exceed 150 mg/ml in a single session. The injection will be pushed gently into the lesion to the point of inducing swelling and blanching of lesion. The lesion shall be bandaged for 01 hour after the injection.
Group B will be advised local anaesthesia with bupivacaine followed intralesional injection of 5 fluorouracil 50mg/ml 0.75ml mixed with 0.25ml triamcinolone acetonide 10mg/ml for every 2cm2 of keloid. Not to exceed 150 mg in a single session. Oral pain killer will be prescribed for 3 days usage after injection in both treatment groups. Treatment in both groups will be repeated every 3 weeks for 4 sessions in total. If there will be large necrotic area after the previous session, it will be allowed to heal before the next session.
A blinded independent medical observer will perform clinical assessment at the end of 12 weeks treatment period using the DKS score for all 88 patients.
Participant satisfaction will be checked by Patient Global Impression-improvement scale, which is a seven-point scale used by patient to report the overall improvement in their disease with treatment as 1: Very much improved, 2: Much improved, 3: Minimally improved, 4: No change, 5: Minimally worse, 6: Much worse and 7: very much worse. Side-effects like severe pain, blistering, infection and eschar formation will be noted in both groups within the 12 weeks treatment period starting from the 1st hour post injection. A blinded dermatologist from our department will keep record of the side-effects.
- Conditions
- Keloids
- Being tested
- Cryotherapy will be done followed by intralesional injection of 5-fluorouracil, Intralesional 5-fluorouracil
- Keywords
- Keloids, Intralesional injectioms, 5-FU
- Medical subject headings
- Keloid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Cryotherapy will be done followed by intralesional injection of 5-fluorouracilDrug
Cryotherapy will be done followed by intralesional injection of 5-FU diluted in steroid, this will be done in phases. Not more than 150mg 5-FU will be used during each session. Session will be repeated after every 3 week for 6 months.
Intralesional 5-fluorouracilDrug
intralesional 5-FU will be given in phases. sessions will be repeated after every 3 weeks for 6 months
| Study group | Role | What they receive |
|---|---|---|
| Cryotherapy followed by intralesional injection of 5-FU | Experimental | Not described Receives: Drug: Cryotherapy will be done followed by intralesional injection of 5-fluorouracil |
| Intralesional injection of 5-FU | Active comparator | Not described Receives: Drug: Intralesional 5-fluorouracil |
What is being measured
The primary outcome is the main question the study is designed to answer.
Side-effects like severe pain, blistering, infection and eschar formation will be noted in both groups within the 12 weeks treatment period starting from the 1st hour post injection
Measured: From enrollment to the end of treatment at 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Apr 2026
- Study start22 Dec 2025
- Primary completion20 Sep 2026 (estimated)
- Study completion20 Sep 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for KeloidsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 88 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sara Khan, Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07531056
- Sponsor's protocol ID
- 1587/EC/14/2025
- Status last verified
- Apr 2026
- First submitted
- 1 Apr 2026
- Last updated
- 24 Apr 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Controlled Trial Comparing The Effectiveness And Safety Of iIntralesional 5 Flourouracil Monotherapy Verses 5 Flourouracil Combined With Cryotherapy; In The Treatment Of Keloid Scars
- ClinicalTrials.gov ID
- NCT07531056
- Acronym / sponsor ID
- 1587/EC/14/2025
- Conditions
- Keloids
- Keywords
- Keloids, Intralesional injectioms, 5-FU
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 88 participants (estimated)
- Lead sponsor
- Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur PakistanUniversity, hospital or other
- Study start
- 22 Dec 2025 (actual)
- Primary completion
- 20 Sep 2026 (estimated)
- Study completion
- 20 Sep 2026 (estimated)
- First posted
- 15 Apr 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn how well intralesional 5 fluorouracil with cryotherapy works to treat keloids as compared to intralesional 5 fluorouracil alone on keloids. It will also learn about the safety of both these treatments. The main questions it aims to answer are:
- What well does cryotherapy followed by intralesional 5 fluorouracil (5FU) work to treat keloids as compared to 5 fluorouracil (5FU) alone?
- What is participant's satisfaction when treated with cryotherapy followed by intralesional 5 fluorouracil (5FU) as compared to 5 fluorouracil (5FU) alone?
- What skin problems do participants have when treated with cryotherapy followed by intralesional 5 fluorouracil (5FU) and 5 fluorouracil (5FU) alone? Researchers will compare cryotherapy followed by intralesional 5 fluorouracil (5FU) with 5 fluorouracil (5FU) alone to see how well both work.
Participants will be divided into two groups:
For Group A: Cryotherapy will be done at lesion site followed by intralesional 5FU every 3 weekly.
For Group B: Intralesional 5FU will be given at lesion site every 3 weekly. Keloids will be assessed at the start of trial and then after 12 weeks of treatment.
Detailed description
The rationale of this study is to find cost-effective treatment regime of cryotherapy with intralesional 5 fluorouracil for keloids. Investigator aim to compare how effective is the combination of cryotherapy followed by intralesional 5 fluorouracil (5FU) as compared to 5 fluorouracil (5FU) alone in the treatment of keloids.
88 patients with keloids consulting the dermatologist in the hospital OPD will be included in the trial after application of the mentioned inclusion and exclusion criteria. After informed consent, a dermatologist will explain the required details of the procedure to the patients and give them their required treatment plan. Participanys will be randomized into two groups by lottery method. Demographic data like age, gender, location, duration, number of keloids, Fitzpatrick skin type, family history of keloids, keloid symptoms (pain, itching or disfigurement), previous treatments (topical steroids, topical silicone sheet or cream, cryotherapy, surgical excision, intralesional steroids or none) will be recorded along with the baseline photograph and rating of severity score based on DSS score. For Group A, Cryotherapy will be done by a spray mini-cryogun ( Brymill B800 Cry-Ac 3 dispenser) using liquid nitrogen targeted at the lesion from the distance of 1 cm and freeze thaw cycles of 30 seconds will be repeated till the lesion freezes to the level of its contact with skin. With larger lesions 2cm2 area will be targeted in a stepwise manner to ensure homogenous cryotherapy of the entire lesion. Local anaesthesia will be given before the cryotherapy with bupivacaine injection, as it relives pain up to 72 hours. 30 minutes after the cryotherapy session intralesional injection of 5 fluorouracil 50mg/ml 0.75ml mixed with 0.25ml triamcinolone acetonide 10mg/ml for every 2cm2 of keloid using a 30-gauge needle with a 3cc syringe. Not to exceed 150 mg/ml in a single session. The injection will be pushed gently into the lesion to the point of inducing swelling and blanching of lesion. The lesion shall be bandaged for 01 hour after the injection.
Group B will be advised local anaesthesia with bupivacaine followed intralesional injection of 5 fluorouracil 50mg/ml 0.75ml mixed with 0.25ml triamcinolone acetonide 10mg/ml for every 2cm2 of keloid. Not to exceed 150 mg in a single session. Oral pain killer will be prescribed for 3 days usage after injection in both treatment groups. Treatment in both groups will be repeated every 3 weeks for 4 sessions in total. If there will be large necrotic area after the previous session, it will be allowed to heal before the next session.
A blinded independent medical observer will perform clinical assessment at the end of 12 weeks treatment period using the DKS score for all 88 patients.
Participant satisfaction will be checked by Patient Global Impression-improvement scale, which is a seven-point scale used by patient to report the overall improvement in their disease with treatment as 1: Very much improved, 2: Much improved, 3: Minimally improved, 4: No change, 5: Minimally worse, 6: Much worse and 7: very much worse. Side-effects like severe pain, blistering, infection and eschar formation will be noted in both groups within the 12 weeks treatment period starting from the 1st hour post injection. A blinded dermatologist from our department will keep record of the side-effects.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Cryotherapy followed by intralesional injection of 5-FU | Experimental | Drug: Cryotherapy will be done followed by intralesional injection of 5-fluorouracil |
| Intralesional injection of 5-FU | Active comparator | Drug: Intralesional 5-fluorouracil |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (3 listed)
- Patients willing to participate in the study
- Patients of age group of 18 -50 years.
- Patients having symptomatic keloids i.e., having pain, pruritus, restriction of movement, scar tension or disfigurement.
Key exclusion criteria (6 listed)
- :• Pregnant women or lactating women
- Patients with history of hepatic, renal, cardiac diseases or chronic diarrhea.
- Patients on immunosuppressant medications due to other diseases
- Patients having myelosuppression checked by CBC.
- Patient taking warfarin.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Cryotherapy will be done followed by intralesional injection of 5-fluorouracilCryotherapy will be done followed by intralesional injection of 5-FU diluted in steroid, this will be done in phases. Not more than 150mg 5-FU will be used during each session. Session will be repeated after every 3 week for 6 months. | Drug | Cryotherapy followed by intralesional injection of 5-FU |
| Intralesional 5-fluorouracilintralesional 5-FU will be given in phases. sessions will be repeated after every 3 weeks for 6 months | Drug | Intralesional injection of 5-FU |
Primary outcome
Side-effects like severe pain, blistering, infection and eschar formation will be noted in both groups within the 12 weeks treatment period starting from the 1st hour post injection
Time frame: From enrollment to the end of treatment at 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2026.
Related trials for Keloids
Not yet recruiting
Fractional Radiofrequency With Streroids Versus Fractional CO2 Laser With Steroids in the Treatment of Keloids
Keloids
Active, not recruiting
Transdermal Versus Intralesional Betamethasone for Keloids
Keloid
RecruitingPhase 2
Ritlecitinib in Patients With Keloids or Those Undergoing Keloidectomy
Keloid
Recruiting
Radiotherapy for Keloids
Keloid
Not yet recruitingPhase 2
siRNA Microneedle Patches for Ear Keloid Post-Surgical Scars
Keloid of Ear Lobe
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Cryotherapy will be done followed by intralesional injection of 5-fluorouracil and Intralesional 5-fluorouracil in people with Keloids, run by Combined Military Hospital (CMH) institute of Medical Sciences Bahawalpur Pakistan at 1 site in Pakistan.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Pakistan. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Side-effects like severe pain, blistering, infection and eschar formation will be noted in both groups within the 12 weeks treatment period starting from the 1st hour post injection (time frame: From enrollment to the end of treatment at 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026.